Purolea Cosmetics Lab drug products were adulterated by insanitary conditions and manufacturing failures, and two Dermveda products are unapproved new drugs.
What happened
FDA inspected Purolea Cosmetics Lab's drug manufacturing facility in Livonia, Michigan, from October 28 to 30, 2025. Investigators found insects, filth, leaves and clutter in several areas, a docking bay door that opened directly to manufacturing, finished homeopathic drugs released without microbial testing, and components used without adequate identity or quality testing, which FDA cited as current good manufacturing practice (CGMP) failures. FDA also reviewed labels for Dermveda Extra Strength Shingles Relief and Dermveda Extra Strength Ultra Genital Herpes Relief and found them to be unapproved new drugs.
What FDA found
The facility had insects, filth, leaves and clutter in several areas, and a docking bay door that opened directly to manufacturing, so drugs were made under insanitary conditions.
FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)The firm released finished homeopathic drugs without testing each batch for total counts and objectionable microorganisms.
21 CFR 211.165(b)The firm did not adequately test components for identity, purity, strength and quality, did not verify supplier certificates of analysis, and did not test high-risk ingredients for identity and contamination before use.
21 CFR 211.84(d)(1), (d)(2), and (d)(6)The quality control unit did not ensure procedures were followed, batch records were reviewed before release, or adequate production controls were established.
21 CFR 211.22(a), 211.22(d), and 211.100(a)The firm used AI-generated specifications, procedures, and master records without review by an authorized human quality representative, and it did not validate processes before distribution.
21 CFR 211.22(c) and 21 CFR 211.100The firm sold Dermveda Extra Strength Shingles Relief and Dermveda Extra Strength Ultra Genital Herpes Relief as drugs for shingles and genital herpes without FDA-approved applications.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
What FDA wants
FDA tells Purolea to correct the violations promptly and respond in writing within 15 working days, including NDC-level information on discontinued drugs, plans for products still within expiry, complaint and recall commitments, notice before resuming manufacturing, and, if it resumes current good manufacturing practice (CGMP) activities, a qualified consultant's six-system audit.
Who should pay attention
- brands that buy homeopathic drugs or cosmetics from contract manufacturers
- companies that rely on supplier certificates of analysis without verification
- drugmakers using AI to draft or maintain manufacturing documents
This is a summary. Read the original letter on fda.gov.